Together, results from our research supports the clinical usage of anti-WEE1 therapy for ER+ breasts tumors which have obtained level of resistance to endocrine therapy and so are intrinsically resistant to CDK4/6 inhibitors
Together, results from our research supports the clinical usage of anti-WEE1 therapy for ER+ breasts tumors which have obtained level of resistance to endocrine therapy and so are intrinsically resistant to CDK4/6 inhibitors. Methods and Materials Reagents Ribociclib (LEE011), palbociclib (PD0332991), fulvestrant (ICI 182,780), tamoxifen (4-hydroxytamoxifen) and Adavosertib (AZD1775) were purchased from Selleck Chemical substances … Read more